In response to the above letter, our study aimed to uncover molecular mechanisms and networks of gene expression regulating telomere maintenance mechanisms (TMM) in liposarcoma (Lafferty-Whyte et al., 2009 ). An important aspect of our study was to derive several gene signatures associated with TMM, but we also showed network analysis and functional validation including QPCR and western blotting for some of the signature gene products in a range of cell lines. Tumours of mesenchymal origin including liposarcomas are underserved in cancer biology, and we welcome advances made through peer-reviewed publication in this field. For reasons described below, we are largely limiting this response to the data set presented to us in March 2010. Although the letter makes some interesting points, it is a very preliminary analysis and so its conclusions must remain unsubstantiated. However, a number of technical differences between our respective analyses are described below. Interestingly, despite these differences it would appear that the new data set supports the conclusions made in our publication.
As the authors suggest, discrepancies between the studies may be due to different microarray platforms as Affymetrix and Agilent probe designs are quite different. Importantly, some genes on our signature may not have corresponding Affymetrix probe sets. This is a potentially critical issue, and the authors appear to confirm the absence of some genes from their analysis in the legend to Figure 1 of their letter. Additionally, the authors have pre-selected the single probe set with highest median expression across the data set. In contrast, we specifically identified probes having divergent expression between TMM. It is therefore unlikely that their gene list is identical to ours or their probe set comparable. Indeed, no details of the specific probes used for clustering are given in their GEO submission, which is not associated with any publication.
We also note that some sample handling information is missing from the submission: although fresh freezing is specified in previous publications on the referenced part of the set provided by the Fox Chase Cancer Centre (Johnson et al., 2005 (Johnson et al., , 2007 , no information is given for the unpublished samples provided from other sources cited in the submission. This may be an important issue: it is essential to ensure that the main contributing factor to intergroup variation in microarray data is biological and not technical variance. Unfortunately, principal component analysis (PCA) performed on only telomerase and alternative lengthening of telomeres (ALT) samples from the new data set mentioned in the letter above suggests that the technical variation corresponding to the date the arrays were scanned is the largest contributing factor for sample grouping (Figure 1 , below) and outweighs any biological factor, including histological subtype and TMM. This will therefore confound any clustering results.
In addition to the above concerns, we have identified several other important differences, which distinguish the authors' approach from our own. It is widely understood that the results of clustering analysis are strongly influenced by the distance metric used. Although we clearly state in the methods of the original study that Spearman rank correlation was employed, the correspondents have adopted the cosine-angle metric. Therefore, the two clustering analyses are technically incomparable.
We would also argue that the analyses are incommensurable at the sample level (indeed, PCA in Figure 1 below suggests that some of the authors' own samples appear internally incomparable). There are key methodological differences in ALT phenotype characterisation between the studies: the authors of the letter use both telomere restriction fragment (TRF) profile and APB detection (colocalization of promyelocytic leukemia bodies (PML) and TRF2), despite only around 80% concordance between the approaches (Costa et al., 2006) , while we use only APB detection (colocalization of PML and telomere FISH). In particular, some samples presented in the letter above were assigned unknown TMM without testing APB in Johnson et al. (2005) . Our data set for clustering analysis also included human mesenchymal stem cells, which, though absent from the authors' analysis, will of course have contributed to the clustering results in our study. Instead, the authors include liposarcoma samples, which show evidence of neither ALT nor telomerase in addition to the TMM double-positive T39; in our view, inappropriate comparisons will of course have contributed to their clustering results. As the aim of our work was to derive comparative molecular information on samples with well-defined TMM, we specifically excluded these tumour samples.
Following submission of this original rebuttal, a revised version of the letter was produced (the current letter) in which 6/38 samples were reclassified. These changes were: (1) TMM status: PleoT34, PleoT35 and DDT55-all reclassified as NA (tumors that were not clearly ALT or telomerase-positive) rather than telomerase; (2) histology status: LS-NOS T17, LS-NOS T20 and LS-NOS T7-all histologies reclassified from Myx to liposarcoma not otherwise specified. One significant impact of this change was reduction of the total number of telomerase samples from 12 to 9, representing reclassification of 25% of this subset. As none of these has previously published TMM and a large proportion of individual samples have undergone substantial reclassifications, we find it difficult to judge the reliability of the data set and have not re-analysed the data. We are happy to make available on request our communications with the Journal on these matters.
Nevertheless, despite myriad differences in the two approaches and our other concerns as raised above, it is interesting that application of the signature to the dedifferentiated sample subset with known TMM (Figure 1b in the letter) results in correct clustering of seven out of eight samples. In addition to histological similarities, the majority of these samples are the new members of the set (T49-T56) comprising the 2009/2010 scans and are thus also comparable by PCA (Figure 1 , above). Although comprising a small sample number, we are pleased that the authors' results in fact appear to offer some limited independent validation that our signature does indeed distinguish ALT from telomerase in most cases where appropriate samples are compared.
In designing this study, we sought not only to find a gene expression signature capable of distinguishing between ALT and telomerase TMMs, but also to uncover unknown regulatory mechanisms controlling TMM utilisation (Lafferty-Whyte et al., 2009) . The functional and network analyses we performed on the signature in the original study provide evidence of a complex regulatory signalling network operating to control expression of the telomerase genes in ALT. Since publication of this article, the regulatory network we described has been further validated in a new study Data from GEO submission GSE20559 were downloaded and pre-processed using GCRMA, according to the normalisation specified by the authors of the letter, within Partek Genomics Suite. Remapping of the 297-gene signature was achieved using Metacore from GeneGO. All probes present on the HG-U133 Plus 2 array that directly corresponded to genes within the original signature were utilised to more accurately reflect the expression levels of the overall signature. Remapping alone did not substantially improve the technical variation due to scan date.
